122 related articles for article (PubMed ID: 38663183)
1. Prediction of drug-drug interaction risk of P-glycoprotein substrate in drug discovery.
Kido Y; Nanchi I; Matsuzaki T; Watari R; Kiyohara H; Seki N; Okuda T
Drug Metab Pharmacokinet; 2024 Mar; 56():101008. PubMed ID: 38663183
[TBL] [Abstract][Full Text] [Related]
2. Development of Simplified in Vitro P-Glycoprotein Substrate Assay and in Silico Prediction Models To Evaluate Transport Potential of P-Glycoprotein.
Ohashi R; Watanabe R; Esaki T; Taniguchi T; Torimoto-Katori N; Watanabe T; Ogasawara Y; Takahashi T; Tsukimoto M; Mizuguchi K
Mol Pharm; 2019 May; 16(5):1851-1863. PubMed ID: 30933526
[TBL] [Abstract][Full Text] [Related]
3. Blonanserin, a novel atypical antipsychotic agent not actively transported as substrate by P-glycoprotein.
Inoue T; Osada K; Tagawa M; Ogawa Y; Haga T; Sogame Y; Hashizume T; Watanabe T; Taguchi A; Katsumata T; Yabuki M; Yamaguchi N
Prog Neuropsychopharmacol Biol Psychiatry; 2012 Oct; 39(1):156-62. PubMed ID: 22691713
[TBL] [Abstract][Full Text] [Related]
4. The Impact of Endogenous Breast Cancer Resistance Protein on Human P-Glycoprotein-Mediated Transport Assays Using LLC-PK1 Cells Transfected With Human P-Glycoprotein.
Miyamoto R; Nozawa T; Shiozuka K; Tabata K
J Pharm Sci; 2019 Mar; 108(3):1085-1089. PubMed ID: 30339864
[TBL] [Abstract][Full Text] [Related]
5. Quantitative prediction of P-glycoprotein-mediated drug-drug interactions and intestinal absorption using humanized mice.
Miyake T; Tsutsui H; Haraya K; Tachibana T; Morimoto K; Takehara S; Ayabe M; Kobayashi K; Kazuki Y
Br J Pharmacol; 2021 Nov; 178(21):4335-4351. PubMed ID: 34232502
[TBL] [Abstract][Full Text] [Related]
6. Is aspirin a substrate of MDR1/P-glycoprotein?
Singh R; Naik T; Nigam A; Chatterjee S; Rajanna P; Shen H; Iyer R
Xenobiotica; 2020 Oct; 50(10):1258-1264. PubMed ID: 32302241
[TBL] [Abstract][Full Text] [Related]
7. In vitro to in vivo comparison of the substrate characteristics of sorafenib tosylate toward P-glycoprotein.
Gnoth MJ; Sandmann S; Engel K; Radtke M
Drug Metab Dispos; 2010 Aug; 38(8):1341-6. PubMed ID: 20413726
[TBL] [Abstract][Full Text] [Related]
8. In vitro to in vivo evidence of the inhibitor characteristics of Schisandra lignans toward P-glycoprotein.
Liang Y; Zhou Y; Zhang J; Liu Y; Guan T; Wang Y; Xing L; Rao T; Zhou L; Hao K; Xie L; Wang GJ
Phytomedicine; 2013 Aug; 20(11):1030-8. PubMed ID: 23731657
[TBL] [Abstract][Full Text] [Related]
9. P-glycoprotein limits the brain penetration of olopatadine hydrochloride, H1-receptor antagonist.
Mimura N; Nagata Y; Kuwabara T; Kubo N; Fuse E
Drug Metab Pharmacokinet; 2008; 23(2):106-14. PubMed ID: 18445990
[TBL] [Abstract][Full Text] [Related]
10. In vitro P-glycoprotein assays to predict the in vivo interactions of P-glycoprotein with drugs in the central nervous system.
Feng B; Mills JB; Davidson RE; Mireles RJ; Janiszewski JS; Troutman MD; de Morais SM
Drug Metab Dispos; 2008 Feb; 36(2):268-75. PubMed ID: 17962372
[TBL] [Abstract][Full Text] [Related]
11. Establishment of in vitro P-glycoprotein inhibition assay and its exclusion criteria to assess the risk of drug-drug interaction at the drug discovery stage.
Sugimoto H; Matsumoto S; Tachibana M; Niwa S; Hirabayashi H; Amano N; Moriwaki T
J Pharm Sci; 2011 Sep; 100(9):4013-23. PubMed ID: 21678427
[TBL] [Abstract][Full Text] [Related]
12. Impact of In Vitro Passive Permeability in a P-gp-transfected LLC-PK1 Model on the Prediction of the Rat and Human Unbound Brain-to-Plasma Concentration Ratio.
Nicolaï J; Chapy H; Gillent E; Saunders K; Ungell AL; Nicolas JM; Chanteux H
Pharm Res; 2020 Aug; 37(9):175. PubMed ID: 32856111
[TBL] [Abstract][Full Text] [Related]
13. Role of P-glycoprotein in the distribution of the HIV protease inhibitor atazanavir in the brain and male genital tract.
Robillard KR; Chan GN; Zhang G; la Porte C; Cameron W; Bendayan R
Antimicrob Agents Chemother; 2014; 58(3):1713-22. PubMed ID: 24379203
[TBL] [Abstract][Full Text] [Related]
14. Effects of the inhibition of intestinal P-glycoprotein on aliskiren pharmacokinetics in cynomolgus monkeys.
Tsukimoto M; Ohashi R; Torimoto N; Togo Y; Suzuki T; Maeda T; Kagawa Y
Biopharm Drug Dispos; 2015 Jan; 36(1):15-33. PubMed ID: 25264342
[TBL] [Abstract][Full Text] [Related]
15. Retrospective analysis of P-glycoprotein-mediated drug-drug interactions at the blood-brain barrier in humans.
Sugimoto H; Hirabayashi H; Amano N; Moriwaki T
Drug Metab Dispos; 2013 Apr; 41(4):683-8. PubMed ID: 23340958
[TBL] [Abstract][Full Text] [Related]
16. P-glycoprotein differentially affects escitalopram, levomilnacipran, vilazodone and vortioxetine transport at the mouse blood-brain barrier in vivo.
Bundgaard C; Eneberg E; Sánchez C
Neuropharmacology; 2016 Apr; 103():104-11. PubMed ID: 26700248
[TBL] [Abstract][Full Text] [Related]
17. P-glycoprotein limits the brain penetration of nonsedating but not sedating H1-antagonists.
Chen C; Hanson E; Watson JW; Lee JS
Drug Metab Dispos; 2003 Mar; 31(3):312-8. PubMed ID: 12584158
[TBL] [Abstract][Full Text] [Related]
18. Calculation of an Apical Efflux Ratio from P-Glycoprotein (P-gp) In Vitro Transport Experiments Shows an Improved Correlation with In Vivo Cerebrospinal Fluid Measurements in Rats: Impact on P-gp Screening and Compound Optimization.
Fischer H; Senn C; Ullah M; Cantrill C; Schuler F; Yu L
J Pharmacol Exp Ther; 2021 Mar; 376(3):322-329. PubMed ID: 33288523
[TBL] [Abstract][Full Text] [Related]
19. Role of P-glycoprotein on the brain penetration and brain pharmacodynamic activity of the MEK inhibitor cobimetinib.
Choo EF; Ly J; Chan J; Shahidi-Latham SK; Messick K; Plise E; Quiason CM; Yang L
Mol Pharm; 2014 Nov; 11(11):4199-207. PubMed ID: 25243894
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
